文献速递脊柱关节炎

Deucravacitinib治疗活动性银屑病关节炎:3期POETYK PsA-2试验52周疗效与安全性

Deucravacitinib in Active Psoriatic Arthritis: Efficacy and Safety Up to 52 Weeks From the Randomized, Double-Blind, Phase 3 POETYK PsA-2 Trial.
PubMed 文献 · Arthritis Rheumatol · 2026-07-20

POETYK PsA-2是一项52周双盲安慰剂对照3期试验,729例生物制剂初治或TNF抑制剂经治的活动性PsA患者随机接受deucravacitinib 6mg每日一次、安慰剂或阿普米司特。第16周deucravacitinib组ACR20应答率显著高于安慰剂(54.2% vs 39.4%,P=0.0002),应答持续至第52周,安全性良好。

要点

  • Deucravacitinib 6mg每日一次在第16周ACR20应答显著优于安慰剂。
  • 应答在16周后继续改善并维持至52周,安慰剂转deucravacitinib组ACR20达67.3%。
  • 52周内无新安全性信号、死亡或心血管事件、恶性肿瘤、机会性感染失衡。

核心结论

  • Deucravacitinib在活动性银屑病关节炎患者中耐受性良好,在多个临床终点和患者报告结局上优于安慰剂。
  • 临床应答和患者报告结局维持至第52周。

研究设计与样本

  • 52周、双盲、安慰剂对照的3期POETYK PsA-2研究(NCT04908189)。
  • 729例对生物制剂DMARD初治或接受过TNF抑制剂的患者随机按3:3:1分配至deucravacitinib 6mg每日一次、安慰剂或阿普米司特30mg每日两次(安全性参考臂),至第16周。
  • 第16至52周,患者继续deucravacitinib或阿普米司特,或从安慰剂转换为deucravacitinib。
  • 主要终点为第16周ACR20应答;次要终点按预设顺序分析以控制多重性。

主要发现

  • 第16周deucravacitinib组ACR20应答率54.2%,安慰剂组39.4%(P=0.0002)。
  • 应答在16周后改善并维持至52周:deucravacitinib-deucravacitinib组62.2%,安慰剂-deucravacitinib组67.3%。
  • 第16周deucravacitinib vs 安慰剂在HAQ-DI、PASI75、SF-36 PCS和MDA达标等分层次要终点上差异显著。
  • 第16周严重不良事件发生率:安慰剂1.0%、deucravacitinib 1.9%、阿普米司特3.8%。
  • 至52周无新安全性信号、死亡或心血管事件、恶性肿瘤、机会性感染失衡。

关键数值与推荐

  • 主要终点第16周ACR20:deucravacitinib 54.2% vs 安慰剂39.4%(P=0.0002)。
  • 第52周ACR20:deucravacitinib-deucravacitinib组62.2%,安慰剂-deucravacitinib组67.3%。
  • 第16周严重不良事件:安慰剂1.0%、deucravacitinib 1.9%、阿普米司特3.8%。

临床怎么用

  • 对于生物制剂初治或TNF抑制剂经治的活动性PsA患者,deucravacitinib 6mg每日一次可考虑作为口服治疗选择。
  • 治疗16周可见ACR20应答显著优于安慰剂,应答可维持至52周。
  • 安全性方面至52周无新信号,但需关注严重不良事件发生情况。

局限性

  • 原文摘要未报告研究局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To assess the efficacy and safety of deucravacitinib, an oral, selective tyrosine kinase 2 inhibitor, in patients with psoriatic arthritis (PsA) who were naive to biologic disease-modifying antirheumatic drugs or received tumor necrosis factor inhibitors. METHODS: In the 52-week, double-blind, placebo-controlled, phase 3 Program for Evaluation of TYK2 Inhibitor (POETYK) PsA-2 study (NCT04908189), patients were randomized 3:3:1 to deucravacitinib 6 mg daily, placebo, or apremilast 30 mg twice daily (safety reference arm) through week 16 (W16). From W16 to W52, patients continued receiving deucravacitinib or apremilast or switched from placebo to deucravacitinib. The primary endpoint was American College of Rheumatology 20% improvement in response (ACR20) at W16. Secondary endpoints were analyzed per prespecified order to control for multiplicity. RESULTS: Overall, 729 patients were randomized (312 deucravacitinib, 312 placebo, 105 apremilast). Significantly more patients achieved ACR20 at W16 with deucravacitinib versus placebo (54.2% vs 39.4%; P = 0.0002); responses improved beyond W16 and were maintained through W52 (deucravacitinib-deucravacitinib, 62.2%; placebo-deucravacitinib, 67.3%). At W16, significant differences in deucravacitinib versus placebo were observed in hierarchical secondary endpoints of Health Assessment Questionnaire Disability Index, 75% improvement in the Psoriasis Area and Severity Index, 36-Item Short Form Survey Physical Component Summary, and achievement of minimal disease activity. At W16, serious adverse events occurred in 1.0%, 1.9%, and 3.8% of patients receiving placebo, deucravacitinib, and apremilast, respectively. No new safety signals, deaths, or imbalances in cardiovascular events, malignancies, or opportunistic infections occurred through W52. CONCLUSION: Deucravacitinib was well tolerated in patients with PsA and demonstrated superior efficacy versus placebo across multiple clinical endpoints and patient-reported outcomes, including functional ability and quality of life. Clinical responses and patient-reported outcomes were maintained through W52.

来源:Arthritis Rheumatol,查看原文。版权归原作者所有。

引用

  1. Mease PJ, Chandran V, Armstrong AW, et al. Deucravacitinib in Active Psoriatic Arthritis: Efficacy and Safety Up to 52 Weeks From the Randomized, Double-Blind, Phase 3 POETYK PsA-2 Trial. Arthritis Rheumatol. 2026. PMID: 42473780. doi:10.1002/art.70280

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。